Latest News and Press Releases

CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the...

CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the...

CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has...

Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, N.J., July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics...

CRANBURY, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has submitted a Japanese new drug...

CRANBURY, N.J., June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate...

Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics,...

CRANBURY, N.J., May 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD),  has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical...

Mean Six-Minute Walk Distance at Month Six Improved in ERT-Naïve Patients (+52 Meters) and ERT-Switch Patients (+38 Meters) Muscle Function Improved in 9 out of 10 Patients Pulmonary Function...

CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird,...